Skip to Main Content

Paper Details

Therapeutically Targetable ALK Mutations in Leukemia.
Cancer Res
16
2015
ALK, ALK Mutations, ALK kinase, ALK mutations, B, B-cell acute lymphoblastic leukemia, Leukemia, acute myelogenous leukemia, crizotinib, cytokine, leukemia, leukemias, mouse, patients, tumors
Anaplastic Lymphoma Kinase, Animals, Cell Line, Tumor, Crizotinib, Drug Resistance, Neoplasm, High-Throughput Nucleotide Sequencing, Humans, Leukemia, Myeloid, Acute, Mice, Molecular Targeted Therapy, Mutation, Precision Medicine, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein Kinase Inhibitors, Pyrazoles, Pyridines, Receptor Protein-Tyrosine Kinases
Author NameAffiliation
Julia E MaxsonKnight Cancer Institute, Oregon Health and Science University
Monika A DavareKnight Cancer Institute, Oregon Health and Science University
Monika A DavareKnight Cancer Institute, Oregon Health and Science University
Samuel B LutyKnight Cancer Institute, Oregon Health and Science University
Christopher A EideKnight Cancer Institute, Oregon Health and Science University, Oregon. Howard Hughes Medical Institute
Bill H ChangKnight Cancer Institute, Oregon Health and Science University
Marc M LoriauxKnight Cancer Institute, Oregon Health and Science University
Cristina E TognonKnight Cancer Institute, Oregon Health and Science University, Oregon. Howard Hughes Medical Institute
Daniel BottomlyKnight Cancer Institute, Oregon Health and Science University, Oregon. Oregon Clinical and Translational Research Institute
Beth WilmotKnight Cancer Institute, Oregon Health and Science University, Oregon. Oregon Clinical and Translational Research Institute
Shannon K McWeeneyKnight Cancer Institute, Oregon Health and Science University, Oregon. Oregon Clinical and Translational Research Institute
Brian J DrukerKnight Cancer Institute, Oregon Health and Science University, Oregon. Howard Hughes Medical Institute
Jeffrey W TynerKnight Cancer Institute, Oregon Health and Science University
  • 1 - 13

Datasets

Release 1.2